Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Flu cases are rising with a strain that makes older people sicker - 25 Advancement Developments in Biotechnology
- 3Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
- 4French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- 5France's Senate backs ban on social media platforms for under-15s
- Korean Air takes emergency action as fuel prices soar
- 2025 Was Another Exceptionally Hot Year
- Vote In favor of Your Favored Web-based Venture Stage
- Why haven’t humans been back to the moon in over 50 years?
- Figure out How to Keep up with and Clean Your Brilliant Bed for Ideal Execution
- We may have less control over how long we live than previously thought
- The architect of Iran’s military survival remains defiant
- New heart disease calculator predicts 30-year risk for young adults
- Figure out How to Explore the Infotainment Framework in the Slam 1500.
